Open AccessLong-term Outcome of Adenosine A2A Receptor Antagonist on Lower Urinary Tract Symptoms in Male Parkinson Disease Patients
Author(s) -
Takeya Kitta,
Ichiro Yabe,
Yukiko Kanno,
Madoka Higuchi,
Mifuka Ouchi,
Mio Togo,
Kyoji Moriya,
Ikuko Takahashi,
Masaaki Matsushima,
Hidenao Sasaki,
Nobuo Shinohara
Publication year - 2018
Publication title -
clinical neuropharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.486
H-Index - 78
eISSN - 1537-162X
pISSN - 0362-5664
DOI - 10.1097/wnf.0000000000000281
Subject(s) - medicine , overactive bladder , lower urinary tract symptoms , international prostate symptom score , urinary system , parkinson's disease , quality of life (healthcare) , urinary urgency , disease , urology , prostate , alternative medicine , nursing , pathology , cancer
In addition to motor symptoms, bladder dysfunction is a major clinical issue in patients with Parkinson disease (PD). Istradefylline is adenosine A2A receptor antagonist approved for PD patients with wearing-off symptoms. The aim of this study was to determine the long-term effects of istradefylline on lower urinary tract symptoms (LUTSs) in PD patients.